This landmark medical trial tests once-daily oral acebilustat treatment over 48 weeks could be the first to determine proof-of-idea for an anti-inflammatory treatment specifically made to prevent long-term lack of lung function in CF individuals. The study will check once daily oral doses of 50 mg and 100 mg acebilustat against placebo along with history therapy in adult CF sufferers. Related StoriesLenvatinib trial gives hope for thyroid malignancy patientsGenetic carrier screening: an interview with Don Hardison, CEO of Good Begin GeneticsClinical trial suggests HIV sufferers should start therapy sooner instead of laterAcebilustat can be a first-in-class neutrophil modulator that handles a key inflammatory signal overexpressed in CF and other orphan inflammatory diseases.Swedish researchers have discovered that reducing the anxiety of a kid before a surgical procedure requires flexible approaches, which could have implications for all nerve-racking hospital procedures involving children. The scholarly study concentrated on critical incidents in relation to the induction of anesthesia. Among the findings were that: The absence of sufficient advance information regarding the child made it difficult for the nurse anaesthetists to help make the necessary preparations.

Other articles from "clinical laboratory":

Random articles